OptimizeRx earnings release, August 12, 2026

OptimizeRx Corp (OPRX) · Form 8-K, Item 2.02 · Filed · SEC filing

OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

-

Q2 revenue totals $20.5 million

-

Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively

-

Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 - $25 million

-

Completed debt refinancing with $35 million traditional banking facility, including $25 million term loan and $10 million undrawn revolver; repaid $8.3 million of principal since inception

WALTHAM, MA. – August 12, 2026 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the three months ended June 30, 2026.

Financial Highlights

• Revenue decreased 30% to $20.5 million in Q2 2026, compared to $29.2 million in Q2 2025.

• GAAP net loss of $(0.7) million or $(0.04) per basic and diluted share in Q2 2026, compared to GAAP net income of $1.5 million, or $0.08 per basic and diluted share, in Q2 2025.

• Non-GAAP net income of $3.1 million, or $0.16 per diluted share in Q2 2026, compared to Non-GAAP net income of $3.7 million or $0.19 per diluted share, in Q2 2025. (See *

Non-GAAP Measures below)

• Adjusted EBITDA of $4.9 million in Q2 2026 compared to $5.8 million in Q2 2025. (See *

Non-GAAP Measures below)

• Cash and cash equivalents of $24.1 million as of June 30, 2026 compared to $23.4 million as of December 31, 2025.

Stephen L. Silvestro, OptimizeRx CEO commented, “Second quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and resilience in our operating model. While year-over-year revenue declined and contracted revenue remains below prior-year levels, these trends are concentrated among a small number of customers, and we are encouraged by increased investment across other portions of our customer base. Our continued investment in platform capabilities, including recent product launches and expanded programmatic initiatives, is strengthening customer engagement as we move into the 2027 planning cycle. Despite some variability in second-half timing and mix, our first-half performance and commercial momentum give us confidence to reiterate full-year 2026 guidance of $95 million to $100 million in revenue and $21 million to $25 million in adjusted EBITDA. We also expanded the long-term opportunity for OptimizeRx through three platform advancements: DeepIntent became the first healthcare demand-side platform (DSP) to integrate our authenticated electronic health record (EHR) network, we launched our patent-pending Natural Language Audience Builder, and we introduced CopayCue, our next-generation copay activation solution. These innovations strengthen our position in artificial intelligence (AI)-enabled audience intelligence, programmatic point-of-care activation, and clinical workflow engagement while creating opportunities for recurring growth.

“Finally, we continued to strengthen our balance sheet by paying down $5.3 million of term loan principal during the quarter—$5.0 million ahead of schedule—and an additional $3.0 million subsequent to quarter-end. We believe our disciplined execution, expanding technology platform, improving customer engagement, and strong financial position leave us well positioned to create meaningful long-term shareholder value.”

2026 Financial Outlook

The Company is reiterating its fiscal year 2026 guidance, and expects revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million.

Conference Call

Date: Wednesday, August 12, 2026

Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)

Toll Free: 1-877-407-9716

International: 1-201-493-6779

Conference ID: 13761843

Call Me

: https://callme.viavid.com/viavid/?callme=true&passcode=13760191&h=true&info=company-email&r=true&B=6

Webcast

: https://viavid.webcasts.com/starthere.jsp?ei=1770269&tp_key=7d483832d3

Webcast Replay:

The archived webcast will be on the investor relations section of the OptimizeRx website.

Individual Meeting Invitation

In an effort to increase relations with institutional investors, OptimizeRx management has dedicated time to hosting individual meetings with portfolio managers and analysts. If you are interested in scheduling a meeting with OptimizeRx management, please contact: adsilva@optimizerx.com or dfarrell@lifesciadvisors.com.

*Non-GAAP Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons why we believe these measures provide useful information to investors and, for historical periods, a reconciliation of these measures to the most directly comparable GAAP measures are included in the supplemental tables that follow.

Although the Company provides guidance for adjusted EBITDA, a non-GAAP financial measure, it is not able to provide guidance to the most directly comparable GAAP measure. Reconciliations for forward-looking figures would require unreasonable effort at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, other income, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

**Definition of Key Performance Indicators

Top 20 pharmaceutical manufacturers:... (truncated)ators to be based upon Fierce Pharma’s most updated list of “The top 20 pharma companies by 2025 revenue”. We previously used “The top 20 pharma companies by 2024 revenue”. As a result of this change, prior periods have been restated for comparative purposes.

Net revenue retention

: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).

Revenue per average full-time employee:

We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent period.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and direct-to-consumer (DTC) strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.

Financial statements

Income Statement

Rolling Twelve Months Ended June 30, (in thousands, except percentages)

Rolling Twelve Months Ended June 30, – 2026Rolling Twelve Months Ended June 30, – 2025
Average revenue per top 20 pharmaceutical manufacturers2,6593,095
Percent of total revenue attributable to top 20 pharmaceutical manufacturers5459
Net revenue retention90121
Revenue per average full-time employee750767

Income Statement

For the Three Months Ended June 30, — (in thousands, except share and per share data, unaudited)

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Net revenue20,50429,19540,34851,123
ExpensesCost of revenues, exclusive of depreciation and amortization presented separately below4,81610,5609,72819,144
ExpensesSales and marketing5,5285,86510,25710,850
ExpensesGeneral and administrative3,7023,9097,2158,466
ExpensesResearch and development3,2743,0926,6766,344
ExpensesStock-based compensation2,2081,4884,0363,046
ExpensesDepreciation and amortization1,0641,0742,1282,168
ExpensesTotal expenses20,59225,98840,04050,018
ExpensesIncome from operations-883,2073081,105
Other income (expense)Interest expense-1,127-1,603-2,282-2,899
Other income (expense)Other income38377676
Other income (expense)Interest income8190158177
Other income (expense)Total other expenses, net-1,008-1,476-2,048-2,646
Other income (expense)Income (loss) before provision for income taxes-1,0961,731-1,740-1,541
Other income (expense)Income tax benefit (expense)393-199542874
Other income (expense)Net income (loss)-7031,532-1,198-667
Other comprehensive income (loss), net of tax:Foreign currency translation adjustment1111
Other comprehensive income (loss), net of tax:Comprehensive income (loss)-6921,532-1,187-667
Other comprehensive income (loss), net of tax:Weighted average number of shares outstanding – basic18,785,59618,510,83418,773,63818,490,931
Other comprehensive income (loss), net of tax:Weighted average number of shares outstanding – diluted18,785,59619,015,49618,773,63818,490,931
Other comprehensive income (loss), net of tax:Income (loss) per share – basic-0.040.08-0.06-0.04
Other comprehensive income (loss), net of tax:Income (loss) per share – diluted-0.040.08-0.06-0.04

Income Statement

For the Three Months Ended June 30,

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Net income (loss)-7031,532-1,198-667
Depreciation and amortization1,0641,0742,1282,168
Stock-based compensation2,2081,4884,0363,046
Severance expenses1,7141,744275
Shareholder activist related fees451
CEO search fees225
CMO search fees4040
Other income-38-37-76-76
Amortization of debt issuance costs277437635611
Estimated income tax impact from adjustments*-1,456-819-2,353-1,853
Non-GAAP net income3,1063,6754,9564,180
Non-GAAP net income per shareDiluted0.160.190.260.22
Weighted average shares outstanding:Diluted18,907,88419,015,49618,992,15418,599,906

Income Statement

For the Three Months Ended June 30,

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Net income (loss)-7031,532-1,198-667
Depreciation and amortization1,0641,0742,1282,168
Income tax (benefit) expense-393199-542-874
Stock-based compensation2,2081,4884,0363,046
Severance expenses1,7141,744275
Shareholder activist related fees451
CEO search fees225
CMO search fees4040
Other income-38-37-76-76
Interest expense, net1,0461,5132,1242,722
Adjusted EBITDA4,9385,7698,2567,270

Balance Sheet

(in thousands, except share and per share data)

June 30, 2026 – (unaudited)December 31, 2025
Current assetsCash and cash equivalents24,09623,365
Current assetsAccounts receivable, net of allowance for credit losses of $260 and $260 at June 30, 2026 and December 31, 2025, respectively24,79637,752
Current assetsTaxes receivable2,328752
Current assetsPrepaid expenses and other2,9262,846
Current assetsTotal current assets54,14664,715
Current assetsProperty and equipment, net122106
Other assetsGoodwill70,86970,869
Other assetsPatent rights, net4,2674,586
Other assetsTechnology assets, net6,2816,870
Other assetsTradename and customer relationships, net28,16229,340
Other assetsOperating lease right of use assets452404
Other assetsSecurity deposits and other assets1828
Other assetsTotal other assets110,049112,097
Other assetsTOTAL ASSETS164,317176,918
Current liabilitiesCurrent portion of long-term debt1,2504,255
Current liabilitiesAccounts payable1,3231,636
Current liabilitiesAccrued expenses5,38911,591
Current liabilitiesRevenue share payable8133,086
Current liabilitiesCurrent portion of lease liabilities227193
Current liabilitiesDeferred revenue709503
Current liabilitiesTotal current liabilities9,71121,264
Non-current liabilitiesLong-term debt, net17,75721,421
Non-current liabilitiesLease liabilities, net of current portion246234

Cash Flow

For the Six Months Ended June 30, — (in thousands, unaudited)

For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
OPERATING ACTIVITIES:Net loss-1,198-667
Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization2,1282,168
Adjustments to reconcile net loss to net cash provided by operating activities:Stock-based compensation4,0363,046
Adjustments to reconcile net loss to net cash provided by operating activities:Amortization of debt issuance costs635611
Changes in:Accounts receivable12,9564,700
Changes in:Prepaid expenses and other assets-81-958
Changes in:Accounts payable-313-174
Changes in:Revenue share payable-2,273-2,462
Changes in:Accrued expenses and other liabilities-6,1904,138
Changes in:Operating lease liabilities-29
Changes in:Deferred tax liabilities-184-1,033
Changes in:Taxes receivable and payable-1,576-964
Changes in:Deferred revenue20611
Changes in:NET CASH PROVIDED BY OPERATING ACTIVITIES8,1448,425
INVESTING ACTIVITIES:Purchase of property and equipment-56-37
INVESTING ACTIVITIES:Capitalized software development costs-91
INVESTING ACTIVITIES:NET CASH USED IN INVESTING ACTIVITIES-56-128
FINANCING ACTIVITIES:Cash paid for employee withholding taxes related to the vesting of restricted stock units-63-92
FINANCING ACTIVITIES:Proceeds from term loan, net of issuance costs24,298
FINANCING ACTIVITIES:Repayment of long-term debt-31,603-5,000
FINANCING ACTIVITIES:NET CASH USED IN FINANCING ACTIVITIES-7,368-5,092
FINANCING ACTIVITIES:EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS11
FINANCING ACTIVITIES:NET INCREASE IN CASH AND CASH EQUIVALENTS7313,205
FINANCING ACTIVITIES:CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD23,36513,380
FINANCING ACTIVITIES:CASH AND CASH EQUIVALENTS - END OF PERIOD24,09616,585
SUPPLEMENTAL CASH FLOW INFORMATION:Cash paid for interest1,5663,409
SUPPLEMENTAL CASH FLOW INFORMATION:Cash paid for income taxes1,2231,087
Full release

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s future performance, expected revenues, expected adjusted EBITDA, AI-enabled audience intelligence, programmatic point-of-care activation, clinical workflow engagement creating opportunities for recurring growth, the Company's disciplined execution, expanding technology platform, increased customer investment, and strong financial position leaving the Company to be well-positioned to create meaningful long-term shareholder value, and other statements relating to future performance, plans, and expectations.

These forward-looking statements are based on the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, its subsequent Quarterly Reports on Form 10-Q, and in other filings the Company has made and may make with the Securities and Exchange Commission in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

OptimizeRx Contact

Andy D’Silva, Chief Business Officer adsilva@optimizerx.com

Investor Relations Contact

Douglas Farrell

LifeSci Advisors, LLC dfarrell@lifesciadvisors.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.